We have had a presence in New Zealand since 1973 and operate across two key businesses, Roche Pharmaceuticals and Roche Diagnostics. The ultimate aim of our almost 100 employees across the country is to enable New Zealand patients to gain access to our medicines and diagnostic tests in order to detect illnesses – such as cancer, infectious and cardiovascular disease – early, and to treat them with life-saving and life-changing medicines.

We believe that good health is incredibly precious, but also complex, because every person is unique. We are working to advance the concept of personalised healthcare – to transform people’s lives by delivering care tailored to each individual – helping to prevent, diagnose and treat illnesses more effectively.

We have extraordinary people making all this happen.

New Zealanders have access to 27 Roche medicines, 19 of which are funded by PHARMAC. Beyond this, New Zealand plays an important role in the global research and development (R&D) network for Roche. In fact, Roche is the largest investor in clinical trials in New Zealand, investing more than $20 million over more than 20 years in clinical trials across a range of disease areas. More than 550 New Zealanders currently have access to treatments through these clinical trials.

No matter which part of the business we work, our team understands that life changing discoveries will only matter if the right medicines get to the right patients.